Loading
A phase 2 trial of izalontamab brengitecan and glecirasib in lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., not yet recruiting.
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07827261 by Sichuan Baili Pharmaceutical Co., Ltd., with a registry enrolment figure of 36 participants, started 2026-09 and due to reach its primary completion in 2028-12. Interventions recorded: BL-B01D1; Glecirasib. Conditions listed: Non-small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "Patients with locally advanced or metastatic non-small cell lung cancer;". Sites: China. No results are recorded here; the registry entry is the source.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Izalontamab brengitecan, SystImmune / Sichuan Biokin, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares KRAS G12C-mutant non-small-cell lung cancer, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares SystImmune / Sichuan Biokin, Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.